|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nuclear magnetic resonance based metabolomics and liverdiseases:Recent advances and future clinical applications显示文摘Metabolomics is defined as the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification.It is an'omics'technique that is situated downstream of genomics,transcriptomics and proteomics.Metabolomics is recognized as a promising technique in the field of systems biology for the evaluation of global metabolic changes.During the last decade,metabolomics approaches have become widely used in the study of liver diseases for the detection of early biomarkers and altered metabolic pathways.It is a powerful technique to improve our pathophysiological knowledge of various liver diseases.It can be a useful tool to help clinicians in the diagnostic process especially to distinguish malignant and non-malignant liver disease as well as to determine the etiology or severity of the liver disease.It can also assess therapeutic response or predict drug induced liver injury.Nevertheless,the usefulness of metabolomics is often not understood by clinicians,especially the concept of metabolomics profiling or fingerprinting.In the present work,after a concise description of the different techniques and processes used in metabolomics,we will review the main research on this subject by focusing specifically on in vitro proton nuclear magnetic resonance spectroscopy based metabolomics approaches in human studies.We will first consider the clinical point of view enlighten physicians on this new approach and emphasis its future use in clinical'routine'. | Roland Amathieu Mohamed Nawfal Triba Corentine Goossens Nadia Bouchemal Pierre Nahon Philippe Savarin Laurence Le Moyec | 2016 | World Journal of Gastroenterology2016，22，1： | 6 |
| 2 | Liver insulin-like growth factor 2 methylation in hepatitis C virus cirrhosis and further occurrence of hepatocellular carcinoma显示文摘AIM: To assess the predictive value of the insulinlike growth factor 2 (Igf2) methylation profile for the occurrence of Hepatocellular Carcinoma (HCC) in hepatitis C (HCV) cirrhosis. METHODS: Patients with: (1) biopsy-proven compensated HCV cirrhosis; (2) available baseline frozen liver sample; (3) absence of detectable HCC; (4) regular screening for HCC; (5) informed consent for genetic analysis were studied. After DNA extraction from liver samples and bisulfite treatment, unbiased PCR and DHPLC analysis were performed for methylation analysis at the Igf2 locus. The predictive value of the Igf2 methylation profile for HCC wasassessed by Kaplan-Meier and Cox methods. RESULTS: Among 94 included patients, 20 developed an HCC during follow-up (6.9 ± 3.2 years). The methylation profile was hypomethylated, intermediate and hypermethylated in 13, 64 and 17 cases, respectively. In univariate analysis, two baseline parameters were associated with the occurrence of HCC: age (P = 0.01) and prothrombin (P = 0.04). The test of linear tendency between the three ordered levels of Igf2 methylation and probability of HCC occurrence was significant (Log Rank, P = 0.043; Breslow, P = 0.037; Tarone-Ware, P = 0.039). CONCLUSION: These results suggest that hypomethylation at the Igf2 locus in the liver could be predictive for HCC occurrence in HCV cirrhosis. | Philippe Couvert Alain Carrié Jacques Pariès Jenny Vaysse Audrey Miroglio Antoine Kerjean Pierre Nahon Jamel Chelly Jean-Claude Trinchet Michel Beaugrand Nathalie Ganne-Carrié | 2008 | World Journal of Gastroenterology2008，14，35： | 6 |
| 3 | Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease显示文摘 | Laurent Peyrin–Biroulet Kiarash Khosrotehrani Fabrice Carrat Anne–Marie Bouvier Jean–Baptiste Chevaux Tabassome Simon Frank Carbonnel Jean–Frédéric Colombel Jean–Louis Dupas Philippe Godeberge Jean–Pierre Hugot Marc Lémann Stéphane Nahon Jean–Marc Sabaté | 2011 | Gastroenterology2011，，5： | 3 |
| 4 | PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis显示文摘 | Erwan Guyot Angela Sutton Pierre Rufat Christelle Laguillier Abdellah Mansouri Richard Moreau Nathalie Ganne-Carrié Michel Beaugrand Nathalie Charnaux Jean-Claude Trinchet Pierre Nahon | 2012 | Journal of Hepatology2012，，： | 2 |
| 5 | Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease显示文摘 | Pierre Nahon Adrien Kettaneh Iulia Tengher-Barna Marianne Ziol Victor de Lédinghen Catherine Douvin Patrick Marcellin Nathalie Ganne-Carrié Jean-Claude Trinchet Michel Beaugrand | 2008 | Journal of Hepatology2008，，6： | 1 |
| 6 | Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease显示文摘 | Pierre Nahon Angela Sutton Marianne Ziol Jessica Zucman-Rossi Jean-Claude Trinchet Nathalie Ganne-Carrié | 2015 | Hepat. Oncol2015，，1： | 1 |
| 7 | Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease显示文摘Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with HCV cirrhosis. A striking increase in HCC incidence has been observed during the past decades in most industrialized countries, partly related to the growing number of patients infected by HCV. HCC is currently the main cause of death in patients with HCV-related cirrhosis, a fact that justifies screening as far as curative treatments apply only in patients with small tumors. As a whole, treatment options are similar in patients with cirrhosis whatever the cause. Chemoprevention could be also helpful in the near future. It is strongly suggested that antiviral treatment of HCV infection could prevent HCC occurrence, even in cirrhotic patients, mainly when a sustained virological response is obtained. | Jean-Claude Trinchet Nathalie Ganne-Carrié Pierre Nahon Gisèle N’kontchou Michel Beaugrand | 2007 | World Journal of Gastroenterology2007，13，17： | 1 |
| 8 | Risk factors of anxiety and depression in inflammatory bowel disease显示文摘 | Stéphane Nahon Pierre Lahmek Christelle Durance Alain Olympie Bruno Lesgourgues Jean‐Frédéric Colombel Jean‐Pierre Gendre | 2012 | Inflamm Bowel Dis2012，，11： | 1 |
| 9 | Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients显示文摘AIM: To compare the incidence of spontaneous bacterial peritonitis in cirrhotic outpatients and inpatients undergoing therapeutic paracentesis METHODS: From January 1 to May 31, 2004, 1041 patients from 70 different hospitals underwent 2123 therapeutic abdominal paracentesis (AP) performed as a outpatient procedure in 355 and as inpatient procedure in 686 cases respectively. The following parameters were compared prospectively between outpatients and inpatients: spontaneous bacterial peritonitis (SBP) prevalence, age, gender, cause of cirrhosis, symptoms, score and grade according to Child-Pugh classification, cirrhosis complications, antibiotics treatment, serum creatinine, platelet count and ascitic protein concentration. RESULTS: SBP was observed in 91 patients. In the whole population the SBP prevalence was 8.7% (95%CI: 7.2-10.6) it was 11.7% (95%CI: 9.5-14.3) in inpatients and 3.1% (95%CI: 1.7-5.5) in outpatients (P < 0.00001). SBP prevalence was 8.3% (95%CI: 4.3-15.6) in symptomatic outpatients vs 1.2% (95%CI: 0.4-3.4) in asymptomatic outpatients (P < 0.002). Patients undergoing outpatient AP were significantly different from those undergoing inpatient AP; they were older (61.1 ± 11.1 years vs 59.4 ± 11.7 years; P = 0.028), cause of cirrhosis was less often alcohol (83 .7 vs 88.2%; P < 0.001), Child-Pugh score was lower (8.9 vs 10.1; P < 0.001) and more often B than C (63.7% vs 38%; P < 0.001). In addition, in outpatients the platelet count was higher (161 ± 93 Giga/L vs 143 ± 89 Giga/L; P = 0.003), serum total bilirubin concentration was lower (38.2 ± 60.7 μmol/L vs 96.3 ± 143.3 μmol/L; P < 0.0001), and ascitic protein concentration higher (17.9 ± 10.7 g/L vs 14.5 ± 10.9 g/L; P < 0.001) than in inpatients. CONCLUSION: In asymptomatic cirrhotic outpatients, the incidence of spontaneous bacterial peritonitis is low thus exploratory paracentesis could be avoided in these patients without significant risk. | Jean-Franois Cadranel Jean-Baptiste Nousbaum Christophe Bessaguet Pierre Nahon Eric Nguyen-Khac Richard Moreau Thierry Thévenot Christine Silvain Christophe Bureau Olivier Nouel Christophe Pilette Thierry Paupard Arnaud Pauwels Thierry Sapey Jean-Didier Grangé Albert Tran | 2013 | World Journal of Hepatology2013，5，3： | 1 |
| 10 | Impact of complementary and alternative medicine on the quality of life in inflammatory bowel disease: results from a French national survey显示文摘 | Vered Abitbol Pierre Lahmek Anne Buisson Alain Olympie Cécile Poupardin Stanislas Chaussade Bruno Lesgourgues Stéphane Nahon | 2014 | European Journal of Gastroenterology & Hepatology2014，，3： | 1 |
| 11 | Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study显示文摘 | Pierre Nahon Angela Sutton Pierre Rufat Charles Faisant Chantal Simon Nathalie Barget Jean-Claude Trinchet Michel Beaugrand Liliane Gattegno Nathalie Charnaux | 2007 | European Journal of Gastroenterology & Hepatology2007，，5： | 1 |
| 12 | Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease显示文摘 | Laurent Peyrin–Biroulet Kiarash Khosrotehrani Fabrice Carrat Anne–Marie Bouvier Jean–Baptiste Chevaux Tabassome Simon Frank Carbonnel Jean–Frédéric Colombel Jean–Louis Dupas Philippe Godeberge Jean–Pierre Hugot Marc Lémann Stéphane Nahon Jean–Marc Sabaté | 2011 | Gastroenterology2011，，5： | 1 |
| 13 | Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis显示文摘AIM:To explore the influence of polymorphisms in genes encoding for the chemokines Stromal cell-Derived Factor-1 (SDF-1)/CXCL12 and Monocyte Chemotactic Protein-1 (MCP-1)/CCL2 , or for the chemokine receptor CCR5 on the risks of liver-related death and hepatocellular carcinoma (HCC) occurrence in hepatitis C virus (HCV)-infected patients. METHODS:SDF-1 3'A, MCP-1 (-2518) and CCR5-32 polymorphisms, SDF-1α, Regulated upon Activation Normal T cells Expressed and Secreted (RANTES)/CCL5 and MCP-1 serum levels were determined in 120 HCV-infected patients, included at time of cirrhosis diagnosis and prospectively followed-up. RESULTS:During follow-up, 23/120 (19.1%) patients died and 47/120 (39.1%) developed HCC. Carriers and noncarriers of each genetic marker had similar baseline characteristics estimating the severity of liver disease. The occurrence of death or HCC during follow-up was similar among carriers and noncarriers of each polymorphism. There was no association between the carriage of mutated alleles and chemokine serum levels and the latter were not associated with the risks of death or HCC. CONCLUSION:This study suggests the lack of association of SDF-1 3'A , MCP-1 (-2518) , CCR5-32 polymorphisms with death and HCC occurrence in cirrhotic HCV-infected patients. | Pierre Nahon Angela Sutton Pierre Rufat Chantal Simon Jean-Claude Trinchet Liliane Gattegno Michel Beaugrand Nathalie Charnaux | 2008 | World Journal of Gastroenterology2008，14，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员